 |
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
High resolution crystal structure of calpain i protease core in complex with e64
|
|
Structure:
|
 |
Calpain 1, large [catalytic] subunit. Chain: a. Fragment: residues 27-356. Synonym: calcium-activated neutral proteinase, canp, mu- type, mucanp, micromolar-calpain. Engineered: yes
|
|
Source:
|
 |
Rattus norvegicus. Norway rat. Organism_taxid: 10116. Gene: capn1, cls1. Expressed in: escherichia coli bl21(de3). Expression_system_taxid: 469008.
|
|
Resolution:
|
 |
|
1.90Å
|
R-factor:
|
0.238
|
R-free:
|
0.272
|
|
|
Authors:
|
 |
T.Moldoveanu,R.L.Campbell,D.Cuerrier,P.L.Davies
|
Key ref:
|
 |
T.Moldoveanu
et al.
(2004).
Crystal structures of calpain-E64 and -leupeptin inhibitor complexes reveal mobile loops gating the active site.
J Mol Biol,
343,
1313-1326.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
09-Jun-04
|
Release date:
|
02-Nov-04
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
|
|
P97571
(CAN1_RAT) -
Calpain-1 catalytic subunit
|
|
|
|
Seq: Struc:
|
 |
 |
 |
713 a.a.
322 a.a.
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
|
|
|
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
intracellular
|
1 term
|
 |
|
Biological process
|
proteolysis
|
1 term
|
 |
|
Biochemical function
|
cysteine-type endopeptidase activity
|
2 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Mol Biol
343:1313-1326
(2004)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structures of calpain-E64 and -leupeptin inhibitor complexes reveal mobile loops gating the active site.
|
|
T.Moldoveanu,
R.L.Campbell,
D.Cuerrier,
P.L.Davies.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The endogenous calpain inhibitor, calpastatin, modulates some
patho-physiological aspects of calpain signaling. Excess calpain can escape this
inhibition and as well, many calpain isoforms and autolytically generated
protease core fragments are not inhibited by calpastatin. There is a need,
therefore, to develop specific, cell-permeable calpain inhibitors to block
uncontrolled proteolysis and prevent tissue damage during brain and heart
ischemia, spinal-cord injury and Alzheimer's diseases. Here, we report the first
high-resolution crystal structures of rat mu-calpain protease core complexed
with two traditional, low molecular mass inhibitors, leupeptin and E64. These
structures show that access to a slightly deeper, but otherwise papain-like
active site is gated by two flexible loops. These loops are divergent among the
calpain isoforms giving a potential structural basis for substrate/inhibitor
selectivity over other papain-like cysteine proteases and between members of the
calpain family.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 4.
Figure 4. Close-up of µI-II-inhibitor interactions.
Stereoview of the interactions between leupeptin (green) and E64
(magenta) with calpain µI-II. Residues within domains I
and II are colored blue and cyan, respectively. The residues
found within 4 Å of leupeptin and E64 are colored by atom
type (carbon, yellow; oxygen, red; nitrogen, blue; and sulfur,
orange). Hydrogen-bonding interactions are indicated by dotted
blue lines. (A) and (B) Surface and stick representations of the
calpain µI-II-leupeptin complex. (C) and (D) Stick and
surface representations of the calpain µI-II-E64 complex.
|
 |
Figure 7.
Figure 7. Comparison of calpain's active site with that of
papain and cathepsins K and B. (A) Calpain µI-II-leupeptin
complex. (B) Papain-leupeptin complex (PDB code 1POP). (C)-(F)
Close-up views of active site cleft (rotated about 90° from
(A) and (B)). (C) Calpain µI-II-leupeptin. (D)
Papain-leupeptin. (E) Cathepsin K-E64 (PDB code 1ATK). (F)
Cathepsin B-benzyloxycarbonyl-Arg-Ser(O-Bzl) chloromethylketone
(PDB code 1THE45).
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Elsevier:
J Mol Biol
(2004,
343,
1313-1326)
copyright 2004.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
I.O.Donkor
(2011).
Calpain inhibitors: a survey of compounds reported in the patent and scientific literature.
|
| |
Expert Opin Ther Pat, 21,
601-636.
|
 |
|
|
|
|
 |
J.S.Gilchrist,
T.Cook,
B.Abrenica,
B.Rashidkhani,
and
G.N.Pierce
(2010).
Extensive autolytic fragmentation of membranous versus cytosolic calpain following myocardial ischemia-reperfusion.
|
| |
Can J Physiol Pharmacol, 88,
584-594.
|
 |
|
|
|
|
 |
C.Palermo,
and
J.A.Joyce
(2008).
Cysteine cathepsin proteases as pharmacological targets in cancer.
|
| |
Trends Pharmacol Sci, 29,
22-28.
|
 |
|
|
|
|
 |
D.E.Croall,
L.M.Vanhooser,
and
R.E.Cashon
(2008).
Detecting the active conformation of calpain with calpastatin-based reagents.
|
| |
Biochim Biophys Acta, 1784,
1676-1686.
|
 |
|
|
|
|
 |
I.O.Donkor,
and
R.Korukonda
(2008).
Synthesis and calpain inhibitory activity of peptidomimetic compounds with constrained amino acids at the P2 position.
|
| |
Bioorg Med Chem Lett, 18,
4806-4808.
|
 |
|
|
|
|
 |
J.Qian,
D.Cuerrier,
P.L.Davies,
Z.Li,
J.C.Powers,
and
R.L.Campbell
(2008).
Cocrystal structures of primed side-extending alpha-ketoamide inhibitors reveal novel calpain-inhibitor aromatic interactions.
|
| |
J Med Chem, 51,
5264-5270.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Azuma,
and
T.R.Shearer
(2008).
The role of calcium-activated protease calpain in experimental retinal pathology.
|
| |
Surv Ophthalmol, 53,
150-163.
|
 |
|
|
|
|
 |
R.A.Hanna,
R.L.Campbell,
and
P.L.Davies
(2008).
Calcium-bound structure of calpain and its mechanism of inhibition by calpastatin.
|
| |
Nature, 456,
409-412.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
T.Moldoveanu,
K.Gehring,
and
D.R.Green
(2008).
Concerted multi-pronged attack by calpastatin to occlude the catalytic cleft of heterodimeric calpains.
|
| |
Nature, 456,
404-408.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
D.Cuerrier,
T.Moldoveanu,
R.L.Campbell,
J.Kelly,
B.Yoruk,
S.H.Verhelst,
D.Greenbaum,
M.Bogyo,
and
P.L.Davies
(2007).
Development of calpain-specific inactivators by screening of positional scanning epoxide libraries.
|
| |
J Biol Chem, 282,
9600-9611.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
D.E.Croall,
and
K.Ersfeld
(2007).
The calpains: modular designs and functional diversity.
|
| |
Genome Biol, 8,
218.
|
 |
|
|
|
|
 |
M.Averna,
R.Stifanese,
R.De Tullio,
M.Passalacqua,
E.Defranchi,
F.Salamino,
E.Melloni,
and
S.Pontremoli
(2007).
Regulation of calpain activity in rat brain with altered Ca2+ homeostasis.
|
| |
J Biol Chem, 282,
2656-2665.
|
 |
|
|
|
|
 |
M.Averna,
R.Stifanese,
R.De Tullio,
E.Defranchi,
F.Salamino,
E.Melloni,
and
S.Pontremoli
(2006).
Interaction between catalytically inactive calpain and calpastatin. Evidence for its occurrence in stimulated cells.
|
| |
FEBS J, 273,
1660-1668.
|
 |
|
|
|
|
 |
D.Cuerrier,
T.Moldoveanu,
and
P.L.Davies
(2005).
Determination of peptide substrate specificity for mu-calpain by a peptide library-based approach: the importance of primed side interactions.
|
| |
J Biol Chem, 280,
40632-40641.
|
 |
|
|
|
|
 |
M.Bartoli,
and
I.Richard
(2005).
Calpains in muscle wasting.
|
| |
Int J Biochem Cell Biol, 37,
2115-2133.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|